About FOCINVEZ™

FOCINVEZ™ is the first and only presentation of fosaprepitant that is:

  • a ready-to-use IV solution, without the need for dilution or reconstitution1,2
  • administered directly from the vial using included vial hanger1
  • free of polysorbate 801-3
  • shelf stable for up to 90 days at room temperature1-3*
  • covered by the Amneal PATHways® Patient Support Program

Use the unique HCPCS code J1434 when billing for FOCINVEZ™.4

FOCINVEZ™
(fosaprepitant
injection)1		 Other formulations of
fosaprepitant for
injection3†		 Cinvanti®
(aprepitant injectable
emulsion)5‡		 Akynzeo®
(fosnetupitant/
palonosetron injection)6‡
Injectable directly into vein without need for additional preparation
Free of polysorbate 80
Does not require reconstitution or dilution
Stable at room temperature
Approved for patients
≥6 months of age
Swipe to reveal full product comparison information

*FOCINVEZ™ vials, when kept in original carton, can remain at 20ºC to 25ºC (68ºF to 77ºF) for up to 90 days, or refrigerated at 2ºC to 8ºC (36ºF to 46ºF) until expiration.1

†Includes generic fosaprepitant and Emend® IV (fosaprepitant) for injection.3

‡IV infusion formulation.5,6

Emend® is a registered trademark of Merck & Co., Inc.

Cinvanti® is a registered trademark of Heron Therapeutics, Inc.

Akynzeo® is a registered trademark of Helsinn Healthcare SA, Switzerland.

HCPCS, Healthcare Common Procedure Coding System; IV, intravenous.

FOCINVEZ™ is administered
directly from the vial using
included vial hanger.1

References: 1. Focinvez. Prescribing information. Amneal Pharmaceuticals LLC; 2023. 2. US Food and Drug Administration. Orange book: Approved drug products with therapeutic equivalence evaluations. Accessed May 13, 2024. https://www.accessdata.fda.gov/scripts/cder/ob/search_product.cfm 3. Emend. Prescribing information. Merck and Co., Inc; 2022. 4. CMS. Second quarter, 2024 HCPCS quarterly update. Updated April 17, 2024. Accessed July 26, 2024. https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system/quarterly-update 5. Cinvanti. Prescribing information. Heron Therapeutics, Inc; 2022. 6. Akynzeo. Prescribing information. Helsinn Birex Pharmaceuticals; 2023.

Learn how to order FOCINVEZ™

Go

INDICATIONS

FOCINVEZ™ is a substance P/neurokinin-1 (NK1) receptor antagonist indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of:

  • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin.
  • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).

Limitations of Use:

FOCINVEZ™ has not been studied for the treatment of established nausea and vomiting.

IMPORTANT SAFETY INFORMATION

Contraindications

  • FOCINVEZ™ is contraindicated in patients who are hypersensitive to any component of the product.
  • Concurrent use of FOCINVEZ™ with pimozide is contraindicated.

Warnings and Precautions

  • Clinically Significant CYP3A4 Interactions: Fosaprepitant, a prodrug of aprepitant, is a weak inhibitor of CYP3A4, and aprepitant is a substrate, inhibitor, and inducer of CYP3A4.
    See full Prescribing Information for recommendations regarding contraindications, risk of adverse reactions, and dosage adjustment of FOCINVEZ™ and concomitant drugs.
  • Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis and anaphylactic shock, during or soon after infusion of fosaprepitant have occurred. Monitor patients during and after infusion. If hypersensitivity reactions occur, discontinue the infusion and administer appropriate medical therapy. Do not reinitiate FOCINVEZ™ in patients who experienced these symptoms with previous use.
  • Infusion Site Reactions: Infusion site reactions (ISRs), including thrombophlebitis and vasculitis, have been reported with the use of intravenous fosaprepitant. The majority of severe ISRs were reported with concomitant vesicant (anthracycline-based) chemotherapy administration. Avoid infusion into small veins. Discontinue infusion and administer treatment if a severe reaction develops.
  • Warfarin: Coadministration of fosaprepitant with warfarin, a CYP2C9 substrate, may result in a clinically significant decrease in the international normalized ratio (INR) of prothrombin time. Monitor the INR in patients on chronic warfarin therapy in the 2-week period, particularly at 7 to 10 days, following initiation of FOCINVEZ™ with each chemotherapy cycle.
  • Hormonal Contraceptives: The efficacy of hormonal contraceptives may be reduced during treatment with FOCINVEZ™ and for 1 month following administration of the last dose of either fosaprepitant or oral aprepitant. Advise patients to use effective alternative or back-up methods of contraception.

Adverse Drug Reactions

  • The most common adverse drug reactions in adults (≥2%) treated with FOCINVEZ™ are neutropenia, leukopenia, peripheral neuropathy, anemia, fatigue, diarrhea, asthenia, dyspepsia, urinary tract infection, pain in extremity.
  • Adverse reactions in pediatric patients treated with FOCINVEZ™ are similar to adults.

Drug Interactions

  • Co-administration of FOCINVEZ™ with drugs that are inhibitors or inducers of CYP3A4 may result in increased or decreased plasma concentrations of aprepitant.
  • See full Prescribing Information for a list of clinically significant drug interactions.

Use in Specific Populations

  • Pregnancy: There are insufficient data on the use of fosaprepitant in pregnant women to identify a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes.
  • Lactation: There are no data on the presence of aprepitant in human milk.

To report SUSPECTED ADVERSE REACTIONS, contact Amneal Biosciences, a division of Amneal Pharmaceuticals LLC at 1-877-835-5472 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see accompanying full Prescribing Information.

INDICATIONS

FOCINVEZ™ is a substance P/neurokinin-1 (NK1) receptor antagonist indicated in adults and pediatric patients 6 months of age and older, in combination with other antiemetic agents, for the prevention of:

+

We use cookies for statistical and measurement purposes to help improve our website and allow us and our partners to provide you with more relevant information. By continuing to navigate this site, closing this box, or by clicking Accept, you are indicating your consent to our use of cookies. To find out more, including how to withdraw your consent, click here.

Accept Reject All